Compare Cytokinetics Inc (CYTK) vs Hormel Foods Corp (HRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Hormel Foods Corp — how do they compare? Cytokinetics Inc trades at $82.28 (market cap $11.12B), while Hormel Foods Corp trades at $25.44 (market cap $13.65B). The key difference: Hormel Foods Corp is the larger of the two by market cap, and Hormel Foods Corp pays a 4.72% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | HRL | |
|---|---|---|
Market Cap | $11.12B | $13.65B |
Sector | Technology | Consumer Staples |
52-Week High | $87.26 | $29.91 |
52-Week Low | $33.23 | $19.74 |
Enterprise Value | $11.59B | $15.65B |
Dividend Yield | — | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Hormel Foods (HRL) trades at $24.46, down 1.11% on the day, with a neutral technical outlook and mixed analyst sentiment. The company has beaten earnings estimates for three consecutive quarters, though net income margin has compressed to 3.82% in 2025 from 6.75% in 2024. Recent strategic moves include the sale of its Brazilian Ceratti operations to focus on higher-growth markets, while maintaining its Dividend King status with 60 consecutive years of dividend increases.
The stock presents a value opportunity with a P/E of 28.78 and consensus price target of $26.33 (7.6% upside), but faces margin pressure from input cost inflation and competitive headwinds. The dividend yield of approximately 4.7% provides income support, though earnings stabilization remains key for sustained recovery from multi-year lows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
